Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in C:\inetpub\wwwroot\technology_detail.php on line 331
 Technology Detail


The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

Gene Signature for Invasive Cancer


Stanford Reference:

03-278


Abstract


Stanford researchers have identified a patented gene signature that is a powerful prognostic indicator in cancer. This set of genes, which represents the wound healing response, provides improved risk prediction for death and metastasis compared to traditional criteria (particularly for breast cancer). Further, this “wound healing” signature is primarily induced by the activation of two genes – CSN5 and MYC. This technology has applications for prognostic testing or patient stratification to direct treatment decisions.

Stage of Research
The inventors have demonstrated that breast cancer cells with this wound signature are selectively killed by the proteasome inhibitor bortezomib. They have also characterized the biological role of CSN5 and MYC in the wound healing response.


Applications


  • Diagnostic/prognostic - to predict clinical course in cancer patients
  • Patient stratification - patients with the “wound healing” gene signature may be more responsive to certain therapies, such as CSN5 inhibitors

Advantages


  • Robust predictor of cancer progression
  • Scalable assay

Publications



Related Web Links



Innovators & Portfolio



Patent Status



Date Released

 7/18/2014
 

Licensing Contact


Ximena Ares, Licensing Associate
650-724-0960 (Direct)
Login to Request Information

[-] Map/Timeline

00-252 Isozyme-selective PKC Inhibitors and Activators
03-337 Progenitor profiling for preleukemia diagnosis, leukemia clinical staging, and prognosis of disease progression
04-183 Six-gene Test for Classification of Patients Having Diffuse Large B-Cell Lymphoma

more technologies »

Related Keywords


breast cancer   breast cancer diagnostic   pharmacogenomics   cMYC   disease classification   gene expression profiling   metastatic breast cancer   personalized medicine   prognostic markers   risk stratification   
 

   

  

Also of Interest...
00-252 Isozyme-selective PKC Inhibitors and Activators
03-337 Progenitor profiling for preleukemia diagnosis, leukemia clinical staging, and prognosis of disease progression
04-183 Six-gene Test for Classification of Patients Having Diffuse Large B-Cell Lymphoma

Recently Viewed...
S03-278 Gene Signature for Invasive Cancer